Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer

NCT04724460 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

179

Enrollment

OTHER

Sponsor class

Conditions

Venous Thrombosis
Neoplasms
Anticoagulants

Interventions

DRUG: Long DOAC
DRUG: Short DOAC

Sponsor

Takeshi Morimoto

Collaborators

[object Object]